ccdc115 Antibody

Introduction to CCDC115 Antibody

CCDC115 antibody (e.g., Proteintech 20636-1-AP) is a rabbit-derived polyclonal IgG antibody targeting the CCDC115 protein. It is validated for use in Western blot (WB), immunohistochemistry (IHC), and ELISA, with reactivity across human, mouse, and rat samples . The antibody is generated against a CCDC115 fusion protein (UniProt ID: Q96NT0) and detects a protein of approximately 20 kDa (observed 22–25 kDa due to post-translational modifications) .

Key Parameters

Validation Data:

• WB: Detected in A549 cells, mouse brain tissue, and Y79 cells .

• IHC: Confirmed in human ovarian cancer tissue with optimal antigen retrieval using TE buffer (pH 9.0) .

Role in Liver Hepatocellular Carcinoma (LIHC)

CCDC115 is overexpressed in LIHC tumor tissues and correlates with poor prognosis. Studies using CCDC115 antibody revealed:

• Upregulation in LIHC: Elevated mRNA and protein levels in tumor tissues compared to normal liver cells (e.g., HepG2, Huh-7) .

• Prognostic Biomarker: High CCDC115 expression linked to advanced tumor stages, TP53 mutations, and sorafenib resistance .

• Mechanistic Insights: CCDC115 activates the PI3K-Akt pathway, promoting metastasis and drug resistance .

Golgi Homeostasis Disorders

CCDC115 deficiency disrupts Golgi trafficking, leading to abnormal glycosylation. Key findings:

• Clinical Phenotype: Hepatosplenomegaly, liver failure, and neurological symptoms in patients with CCDC115 mutations .

• Functional Rescue: Complementation with wild-type CCDC115 restored sialic acid labeling in fibroblasts .

Viral Protein Interactions

CCDC115 interacts with classical swine fever virus (CSFV) glycoprotein E2. Antibody-based assays demonstrated:

• Binding Dynamics: E2 residues (K112M, N260I, M275S) mediate interaction with CCDC115 .

• Viral Replication: Disrupting E2-CCDC115 binding reduced CSFV replication in swine macrophages by 10- to 100-fold .

Recommended Protocols

Critical Notes:

• Molecular Weight Discrepancy: Observed 22–25 kDa bands versus the predicted 20 kDa, likely due to glycosylation .

• Cross-Reactivity: Validated in human, mouse, and rat tissues but requires titration for optimal results .